This review aims to examine the emerging therapeutic potential of α7nAChR in HF and HFpEF pathology, focusing on its protective role in modulating the complex interplay between systemic and cardiovascular inflammation, renin-angiotensin-aldosterone system activation, neurocardiac signaling and metabolic dysfunction. This evidence concerns the gene CHRNA7 and hydrops fetalis.